Independent assessment of Mass Drug Administration in filariasis affected Surat city.
The Mass Drug Administration (MDA) done in Surat city (Gujarat) during 2005, revealed good impact on infection and infectivity in mosquitoes and also on microfilaria rate & mean infection density. The overall impact seen was 23% on mf rate, 28% on mean mf density, 65% on infection rate and 50% on infectivity rate in vectors. Indigenous population contribution to microfilaria cases was 9.7%, whereas migratory population contributed 72.2%; predominant 51.9% from Orissa and 20.3% from U.P. Of the total 3640 persons interviewed for MDA compliance in seven zones of the Surat city revealed that actual drug consumption was 76.7% (2792/3640). Another 11.9% although took the drug but did not consume and 11.4% refused. Important reasons for consuming was fear to get the disease (40.7%) and for not consuming; 'will consume after meal' (6.9%), too many tablets (1.7%), seek consent from doctor (1.5%), lack of awareness (1.4%) etc. Refusal was mainly due to the reason as respondents felt apparently healthy. Assessment of IEC activities suggested that main awareness was created by media (local or national TV, banners or handbills, local news papers or mike announcement) alongwith some impact made through NGO's. These observations clearly indicated the utility of effective health education for optimum community participation and shown that it was crucial for successful community based elimination campaign. However some gray areas also suggest the scope for further improvements.
Vaishnav
K G
KG
Vector Borne Diseases Control Department, Surat Municipal Corporation, Surat. keshav_vaishnav@yahoo.com
Patel
I C
IC
D000818:Animals; D004049:Diethylcarbamazine / Q000008:administration & dosage* / Q000627:therapeutic use; D005368:Filariasis / Q000188:drug therapy / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control*; D005369:Filaricides / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008842:Microfilariae / Q000187:drug effects; D010349:Patient Compliance; D015397:Program Evaluation; D016312:Treatment Refusal
D005369:Filaricides; D004049:Diethylcarbamazine